ClinicalTrials.gg
CompletedNCT06792968Updated Apr 13, 2025

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

A Phase 1 interventional study of Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets and Synjardy 5 mg/1000 mg film-coated tablets in Diabetes Mellitus Type 2, sponsored by Gedeon Richter Plc.. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-13.

Sponsored by Gedeon Richter Plc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 277 studies in Diabetes Mellitus, Type 2 with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Russian Federation.

Enrollment
236th of 253
64 · median 542
Started
2025
with 2 others
Phase 1
5 of 277
none open now
Registered
275th of 277
by date

Among the 277 studies in Diabetes Mellitus, Type 2 with a site in Russian Federation, this one is the 236th largest by enrollment of the 253 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 1, and was the 275th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 277 studies in Diabetes Mellitus, Type 2 with a site in Russian Federation is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 277 studies in Diabetes Mellitus, Type 2 with a site in Russian Federation as a file.
02

Study summary

Empagliflozin and metformin hydrochloride are two separate drugs. The combination of these two drugs in one tablet are used for the treatment of type 2 diabetes, along with diet and exercise, and can be used with other drugs, if required. It is approved in Russia and also various other countries. In Russia, the brand name is Synjardy®.

The purpose of this research study is to measure the amount of the two drugs in the blood after taking two different formulations of the combination tablet. One formulation, also called Synjardy®, is an approved product in Russia marketed by Boehringer Ingelheim International GmbH, Germany. The other formulation is an investigational product that is not approved. The data from this study will be used to compare the two products.

Subjects participating in this study will take 5 mg empagliflozin and 1000 mg metformin hydrochloride (1 combination film-coated tablet) of one formulation in each period. The maximum recommended daily dose is 25 mg of empagliflozin and 2,000 mg of metformin hydrochloride which is based on the subject's current regimen, effectiveness, and tolerability.

03

Conditions studied

  • Diabetes Mellitus Type 2

Keywords

  • Diabetes Mellitus Type 2
  • Diabetes
  • Empagliflozin
  • Metformin
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of the written of the volunteer to participate in the study in accordance with the current legislation, volunteer's agreement to observe all study restrictions and consent to come back to the center for providing of all study procedures.
  2. Verified as "healthy" by the Investigator based on the results of the standard clinical and laboratory tests and instrumental investigations, results of physical examination and medical history data;
  3. Male and female volunteers of Caucasian race, aged 18 to 45 years (inclusive) at screening.

    Female volunteers can be with childbearing or non-. Female volunteers of non-childbearing potential are defined as: females with documented menopause (defined as the absence of menstruation for at least 12 consecutive months without an alternative medical cause with follicle-stimulating hormone (FSH) level at screening ≥25 mIU/mL) or females with documented surgical sterilization (hysterectomy, bilateral ovary- or tubectomy, uterine tubes ligation);

  4. (BMI) (by Quetelet) between 18.5 and 30 kg/m2 (inclusive). Body weight must be more than 45 kg and less than 100 kg;
  5. A volunteer must agree the following requirements:

    1. Female volunteers of childbearing potential must confirm the absence of unprotected sexual intercourse with unsterilized partner within 30 days before screening;
    2. Female volunteers must agree to sexual abstinence or to use consistently and correctly one of the adequate methods listed below during their participation in this study and for 30 days after the last dose of the IMP;
    3. Male volunteers must agree to sexual abstinence or together with their female partners of childbearing potential must use consistently and correctly one of the adequate contraceptive methods listed below during their participation in this study and for 30 days after the last dose of the IMP;
    4. Male volunteers must agree to refrain from donating sperm during their participation in this study and for 30 days after the last dose of the IMP;

    Note: Adequate contraceptive methods include:

    • Non-hormonal intrauterine device (IUD);
    • Barrier method in combination with spermicidal drug or diaphragm (diaphragm with spermicide, cervical cap with spermicide, condom with spermicide).
  6. A volunteer has suitable veins for cannulation.

Exclusion criteria

Exclusion Criteria:

  1. Known history or presence of neurologic, hematologic, endocrine (including diabetes mellitus 1 and 2 type), oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results;
  2. Known history or presence of clinically significant disease of the gastrointestinal tract, surgical interventions on gastrointestinal tract (except appendectomy);
  3. Burdened allergological anamnesis, including known history of anaphylactic reaction/anaphylactic shock, known history or presence of or idiosyncratic reaction to empagliflozin or metformin or of the test/reference product, or any other drug substances with similar activity;
  4. Acute or chronic infectious disease within 4 weeks before screening;
  5. History or presence of malignant disease;
  6. Presence of clinically significant hepatic or renal dysfunction as per Investigator's discretion;
  7. Estimated of ≤60 mL/min based on the Cockcroft-Gault equation, or serum creatinine level higher than the of the local laboratory;
  8. Use of medication (prescribed, over-the-counter medications, and natural health products [including herbal remedies, phytohormones, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports]) within 14 days prior to screening and thereafter. It is allowed to use medical products without systemic absorption.
  9. Use of medications with potent effect on hemodynamics, and liver function (barbiturates, omeprazole, cimetidine, etc.) within 30 days before screening and thereafter;
  10. Donation of blood or plasma (450 ml and more) within 2 months before screening;
  11. Blood or plasma transfusion within 1 year before screening;
  12. Results of standard laboratory investigations outside the normal range of the local laboratory, which are considered clinically significant by the Investigator;
  13. abnormalities, including clinically significant arrhythmia, or suspected arrhythmia as judged by the Investigator;
  14. Vital sign abnormalities at the screening (systolic blood pressure [BP] \< 100 or > 130 mmHg, diastolic BP \< 60 or > 90 mmHg, or heart rate [HR] \< 60 or > 90 bpm);
  15. Positive test for , , (HIV), or syphilis. It is allowed to use results of the HIV test, hepatitis viruses B and C tests and syphilis analysis, which were performed within 3 months before screening visit;
  16. Positive test for SARS-CoV-2 using express immunochromatographic test system for qualitative detection of SARS-CoV-2 antigen in smears from the nasopharynx or oropharynx;
  17. Positive urine cotinine test at screening or at Day 0, or smoking cigarettes or tobacco or consuming any nicotine products (patches, chewing gum etc.) during 6 months prior to screening;
  18. Positive alcohol breath test at screening or at Day 0, or history of significant alcohol abuse within one year prior to screening, regular use of alcohol within 6 months prior to screening (more than 10 units of alcohol per week [1 unit = 200 mL of dry wine, 400 mL of beer, or 50 mL of 40% alcohol]), or consumption of alcohol within 72 hours prior to screening/72 hours prior to dosing;
  19. Positive urine screening for narcotic, psychotropic, and potent substances at screening or at Day 0, or history of significant drug abuse or use of illegal drugs (such as marijuana, cocaine, phencyclidine, crack, opioid derivatives including heroin, and amphetamine derivatives).
  20. Positive pregnancy test at screening or at Day 0 (the test is performed to all female volunteers);
  21. Female volunteers who are pregnant or lactating, who wish to get pregnant; female volunteers of with presence of unprotected sexual intercourse with unsterilized partner within 30 days before screening; male subjects who wish to conceive during participation in the study;
  22. Female volunteers who have used hormonal (implanted, injected, intravaginal, or intrauterine hormonal contraceptives within 6 months prior to screening; oral or transdermal hormonal contraceptives within 21 days prior to screening) or wish to use them during participation in the study;
  23. Consumption of food containing poppy seeds within 72 hours prior screening / 72 hours prior to hospitalization in the first period;
  24. Consumption of food or beverages containing xanthine derivatives or xanthine-related compounds (e.g. tea, coffee, cola, chocolates) or energy drinks from 72 hours prior to first dosing;
  25. Consumption of food or beverages containing grapefruit, starfruit, pomegranate, pineapple, or pomelo from 14 days prior to the first dosing;
  26. Dehydration due to diarrhea, vomiting or other causes during the last 24 hours before dosing;
  27. Participation in a clinical trial that involved administration of an medicinal product within 30 days prior to drug administration or within 5 times the half-life of the previous IMP used, whichever is longer, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results;
  28. Difficulties with staying fasting or consuming standardized high-calorie breakfast/other meal provided by the site;
  29. Planned or scheduled surgery within 7 days prior or 7 days after study drugs administration;
  30. Difficulties with swallowing tablets or capsules whole;
  31. Following a special diet within 30 days prior to the first drug administration (e.g., liquid, protein, raw food diet, vegetarian, vegan);
  32. Mental, physical or other reasons that do not allow the volunteer to adequately assess his/her behaviour and correctly fulfil the conditions of the study protocol;
  33. Other diseases/conditions that, in the opinion of the Investigator, may affect the pharmacokinetics of the study drugs or increase the risk for the health of the volunteer;
  34. Any reason which, in the opinion of the Investigator, would prevent the volunteer from participating in the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Empagliflozin + Metformin hydrochloride combination film-coated tablets

    Combination tablet of Empagliflozin + Metformin hydrochloride 5 mg/1000 mg of Gedeon Richter Plc., Hungary

    Drug: Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets

  • Active comparator
    Synjardy® film-coated tablets

    Synjardy 5 mg/1000 mg of Boehringer Ingelheim International GmbH, Germany

    Drug: Synjardy 5 mg/1000 mg film-coated tablets

Interventions

  • DrugEmpagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets

    1 tablet of Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated table

  • DrugSynjardy 5 mg/1000 mg film-coated tablets

    1 tablet of Empagliflozin+Metformin 5 mg/1000 mg filmcoated tablets

06

What researchers measure

Primary outcomes

  1. Bioequivalence of Empagliflozin + Metformin hydrochloride film-coated tablets and Synjardy® film-coated tablets via measuring the AUC from time 0 to last collection time t (AUC0-t)

    The primary purpose of the study is to assess the bioequivalence of Empagliflozin + Metformin hydrochloride 5 mg/1000 mg film-coated tablets (Gedeon Richter Plc., Hungary) and Synjardy 5 mg/1000 mg film-coated tablets (Boehringer Ingelheim International GmbH, Germany) in healthy, adult volunteers under fed conditions. The measurement will be based on two-sided 90% CI for the test to reference ratio of the population means is within 80.00% to 125.00% for each of the Ln-transformed data of AUC.

    Time frame: From enrollment to the end of treatment at about 7 weeks

  2. Bioequivalence of Empagliflozin + Metformin hydrochloride film-coated tablets and Synjardy® film-coated tablets via measuring the maximum concentration in plasma (Cmax)

    The primary purpose of the study is to assess the bioequivalence of Empagliflozin + Metformin hydrochloride 5 mg/1000 mg film-coated tablets (Gedeon Richter Plc., Hungary) and Synjardy 5 mg/1000 mg film-coated tablets (Boehringer Ingelheim International GmbH, Germany) in healthy, adult volunteers under fed conditions. The measurement will be based on two-sided 90% CI for the test to reference ratio of the population means is within 80.00% to 125.00% for each of the Ln-transformed data of Cmax.

    Time frame: From enrollment to the end of treatment at about 7 weeks

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    The secondary purpose is to assess the safety and tolerability of the study products from the signing of the informed consent form (ICF) until the end of the study. There will be no formal statistical evaluation of safety or tolerability. The safety results will be provided as listings and summary tables for each treatment group. Adverse event data listing will include AEs onset and resolution date/time, duration, time from dosing, severity, relationship to the IMP and/or the additional drug product, outcome, and the action taken to the IMP and/or additional drug product and to treat the AE.

    Time frame: From enrollment to the end of treatment at about 7 weeks

07

Study locations

1 site
  • State Budgetary Institution of Healthcare of Yaroslavl region "Yaroslavl Regional Clinical Narcological Hospital
    Yaroslavl, 150054, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Apr 2025, 0 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 0 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Jan 27, 2025
StartActual
Mar 30, 2025
Primary completionActual
Apr 6, 2025
CompletionActual
Apr 8, 2025
Last update
Apr 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06792968
Lead sponsor
Gedeon Richter Plc.
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Mar 30, 2025
Primary completion
Apr 6, 2025
Completion
Apr 8, 2025
Last update
Apr 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion